Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas

Journal of Clinical Oncology

Volumn 19, Issue 13, 2001, Pages 3260-3266

  Grossman, S A ^a   Phuphanich, S ^a   Lesser, G ^a   Rozental, J ^a   Grochow, L B ^a   Fisher, J ^a   Piantadosi, S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; PHENYTOIN; SURAMIN; VALPROIC ACID;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0035398022     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.13.3260     Document Type: Article

References (49)

1. Suramin binds to platelet-derived growth factor and inhibits its biological activity
2. Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin: Implications for the mechanism of autocrine transformation
3. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth-factor-induced mitogenesis by suramin
4. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells
5. Recent developments in the cell biology of basic fibroblast growth factor
6. Transformation of NIH-3T3 cells with basic fibroblast growth factor of the hst/K-fgf oncogene causes down-regulation of the fibroblast growth factor receptor: Reversal of morphological transformation and restoration of receptor number by suramin
7. Suramin, anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A
8. Differential effects of suramin on the coupling of receptors to individual species of pertussistoxin sensitive quanine-nucleotide-binding proteins
9. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
10. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
11. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer
12. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial
13. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group study
14. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation
15. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
16. New drugs in non-Hodgkin's lymphoma
17. Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy
18. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy
19. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients
20. Phase II trial of suramin in patients with metastatic renal cell carcinoma
21. Suramin therapy in AIDS and related disorders
22. Drugs used in the chemotherapy of protoczoal infections
23. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo
24. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection
25. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin
26. Use of adaptive control with feedback to individualize suramin dosing
27. Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer
28. Hemostasis activation in patients undergoing brain tumor surgery
29. Venous thromboembolism and high grade gliomas
30. Treatment of thromboembolic complications in patients with primary brain tumors
31. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions
32. Increased 9-aminocamptothecin requirements in patients on anticonvulsants
33. Dose requirements, pharmacology, and activity of CPT-11 in patients with recurrent high-grade glioma: A NABTT CNS Consortium trial
34. The NABTT CNS Consortium: Organization, objectives, and progress
35. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro
36. Angiogenesis in human gliomas: Prognostic and therapeutic implications
37. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
38. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI
39. Inhibition of platelet-derived growth factor-mediated signal transduction on tumor growth by N-[4-(trifluoromethyl) -phenyl]5-methylisoxazole-4-carboxamide
40. Suramin inhibits glioma cell proliferation in vitro and in the brain
41. Suramin treatment of human glioma xenografts: Effects on tumor vasculature and oxygenation status
42. Suramin inhibits C6 glioma-induced angiogenesis in vitro
43. The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma
44. Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression
45. 14C-suramin readily enters and persists within intracranial malignant gliomas following intravenous administration in rats
46. Response to suramin correlates with tumor growth factor quantification
47. Successful treatment of infantile hemangiomas with interferon-alph-2b
48. Therapeutic synergy of TNP-47 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multifore xenografts
49. The NABTT Glioblastoma Database: An objective means to select novel agents for phase III testing